Beyond QSIT

April 15, 2002
Joseph F. Noferi, Esq.

,
Daniel E. Worden

BioPharm International, BioPharm International-04-01-2002, Volume 15, Issue 4

by Joseph F. Noferi, Pharmacia GS API Biopharma and Daniel E. Worden If a process is out of control, an FDA inspector will find it, eventually. Companies that emerge as winners will be those that embrace compliance as a core business practice. Systems models provide strategic competitive advantage.